184473-60-7

Upstream product

• 184473-59-4 4-bromo-2,5-dimethoxyphenylacetic acid 
• 1758-25-4 (2,5-dimethoxyphenyl)acetic acid 
• 128-08-5 N-Bromosuccinimide 
• 681171-54-0 [2-(2,5-dimethoxy-phenyl)-ethoxy]-dimethyl-silane 
• 7417-19-8 2-(2,5-dimethoxyphenyl)ethanol 
• 75-21-8 oxirane 
• 2674-34-2 1,4-dibromo-2,5-dimethoxybenzene 

Downstream Products

• 184473-61-8 2,5-dihydroxy-4-bromophenethylbromide 
• 681171-56-2 [2-(4-bromo-2,5-dimethoxyphenyl)ethoxy]-tert-butyldimethylsilane 
• 712293-13-5 1-bromo-2,5-dimethoxy-4-(2-methoxymethoxy-ethyl)-benzene 
• 1746-29-8 bromo-4-(2-bromo-ethyl)-2,5-dimethoxy-benzene 
• 40492-53-3 2,3-dihydro-6-bromo-5-hydroxybenzofuran 
• 894803-86-2 N-(4-amino-5-cyano-6-ethoxy-pyridin-2-yl)-2-(4-methanesulfonyl-2,5-dimethoxy-phenyl)-acetamide 
• 894803-69-1 (4-methanesulfonyl-2,5-dimethoxyphenyl)acetic acid 
• 904311-61-1 2-(4-methanesulfonyl-2,5-dimethoxyphenyl)ethanol 
• 894803-66-8 (4-methanesulfonyl-2,5-dimethoxyphenyl)acetyl chloride 
• 894803-67-9 2-(2,5-dimethoxy-4-methylsulfanylphenyl)ethanol 

Relevant academic research and scientific papers

Inhibitors of c-Jun N-terminal kinases

The present invention relates to compounds that are inhibitors of c-jun N-terminal kinase 1, 2, or 3 (JNK1, JNK2, or JNK3), compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by the activation of JNK1, JNK2 and JNK3.

2-amino-6-(2,4,5-substituted-phenyl)-pyridines

The invention provides compounds of formula VI and the pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and R4 are as defined, to pharmaceutical compositions containing such compounds and to the use of such compounds in the treatment and prevention of central nervous system and other disorders. The invention also provides methods for inhibiting neurological damage caused by impairment of glucose and/or oxygen to the brain in a mammal, which method comprises administering to the mammal a NOS inhibitor. In one embodiment, the NOS inhibitor is administered to the mammal prior to surgery, for example prior to cardiac surgery, angioplasty, or angiography.

NOVEL BENZOPYRAN ANALOGS AND THEIR USE FOR THE TREATMENT OF GLAUCOMA

Novel benzopyran analogs are disclosed. Also disclosed are methods for the lowering and controlling of normal or elevated intraocular pressure as well as a method for the treatment of glaucoma using compositions containing one or more of the compounds of

One-pot Claisen rearrangement/O-methylation/alkene isomerization in the synthesis of ortho-methoxylated phenylisopropylamines

An improved synthesis of a potent serotonin agonist 1a and its novel derivative 1b is described, making use of a Claisen rearrangement whose unstable phenolic product is methylated and isomerized in situ. This method may be of general use in the synthesis of α-methoxylated phenethylamine derivatives. The synthesis also includes an unusual, one pot demethylation/primary alcohol bromination with boron tribromide.